PLYMOUTH
MEETING, Pa., Nov. 17,
2022 /PRNewswire/ -- INOVIO (NASDAQ: INO), a
biotechnology company focused on developing and commercializing DNA
medicines to help treat and prevent infectious diseases, cancer,
and diseases associated with HPV, today announced that it has
agreed with its collaborator, the Coalition for Epidemic
Preparedness Innovations (CEPI), to discontinue development of
product candidates targeting Lassa Fever (INO-4500) and Middle East
Respiratory Syndrome (MERS) (INO-4700), following initial analyses
of data from studies conducted by INOVIO and funded by CEPI.
Dr. Jacqueline Shea, INOVIO's
President and Chief Executive Officer, said, "For the past four
years, we have been pleased to collaborate with CEPI on its mission
of accelerating the development of vaccines against epidemic and
pandemic threats so that they can be accessible to all people in
need. Although INO-4500 and INO-4700 were well-tolerated by
participants in our clinical trials and generated immune responses,
the two-dose regimen did not meet CEPI's selection criteria for
further development. We continue to believe in the potential of our
DNA medicine candidates based on their characteristics, including
the ability to elicit durable T-cell responses, which could be
important in the prevention and treatment of infectious diseases.
INOVIO welcomes the opportunity to collaborate with CEPI in the
future."
The INO-4500 Lassa Fever trial was a Phase 1b study involving 220 participants in
Ghana. With this trial, INO-4500
was the first product candidate to enter human clinical trials in
West Africa targeting Lassa Fever.
The INO-4700 trial was a Phase 2 study targeting the prevention of
MERS. The first cohort of the trial involved 192 participants in
Jordan, Kenya, and Lebanon. INOVIO intends to publish data to aid
subsequent research.
About INOVIO
INOVIO is a biotechnology company focused on developing and
commercializing DNA medicines to help treat and protect people from
HPV-associated diseases, cancer, and infectious diseases. INOVIO's
DNA medicines in development are delivered using its
investigational proprietary smart device to produce immune
responses against targeted pathogens and cancers. For more
information, visit www.inovio.com.
Contacts
Investors & Media:
Gene Kim, (267) 589-9471,
gene.kim@inovio.com
Thomas Hong, (267) 440-4298,
thomas.hong@inovio.com
Forward-Looking Statement
This press release contains certain forward-looking statements
relating to our business, our expectations regarding our research
and development programs, including the planned publication of data
from clinical trials. Actual events or results may differ from the
expectations set forth herein as a result of a number of factors,
including uncertainties inherent in pre-clinical studies, clinical
trials, product development programs and commercialization
activities and outcomes, the availability of funding to support
continuing research and studies in an effort to prove safety and
efficacy of electroporation technology as a delivery mechanism or
develop viable DNA medicines, our ability to support our pipeline
of DNA medicine products, the ability of our collaborators to
attain development and commercial milestones for products we
license and product sales that will enable us to receive future
payments and royalties, the adequacy of our capital resources, the
availability or potential availability of alternative therapies or
treatments for the conditions targeted by us or collaborators,
including alternatives that may be more efficacious or cost
effective than any therapy or treatment that we and our
collaborators hope to develop, issues involving product liability,
issues involving patents and whether they or licenses to them will
provide us with meaningful protection from others using the covered
technologies, whether such proprietary rights are enforceable or
defensible or infringe or allegedly infringe on rights of others or
can withstand claims of invalidity and whether we can finance or
devote other significant resources that may be necessary to
prosecute, protect or defend them, the level of corporate
expenditures, assessments of our technology by potential corporate
or other partners or collaborators, capital market conditions, the
impact of government healthcare proposals and other factors set
forth in our Annual Report on Form 10-K for the year ended
December 31, 2021, our Quarterly
Report on Form 10-Q for the quarter ended September 30, 2022, and other filings we make
from time to time with the Securities and Exchange Commission.
There can be no assurance that any product candidate in our
pipeline will be successfully developed, manufactured, or
commercialized, that the results of clinical trials will be
supportive of regulatory approvals required to market products, or
that any of the forward-looking information provided herein will be
proven accurate. Forward-looking statements speak only as of the
date of this release, and we undertake no obligation to update or
revise these statements, except as may be required by law.
View original
content:https://www.prnewswire.com/news-releases/inovio-provides-an-update-on-lassa-fever-and-mers-programs-301682063.html
SOURCE INOVIO Pharmaceuticals, Inc.